Excipients, raw materials and intermediates

Cautious 2003 for DSM

Cautious 2003 for DSM

The global economic downturn marked 2003 first quarter results for
Dutch based life science company DSM but strong autonomous volume
growth boosted figures to higher than 2002.

Investing in peptides

Investing in peptides

US company PPD is taking a stake in Chemokine Therapeutics, a
Canadian- and US-based biotechnology company, to continue
development of a proprietary peptide derived from a particular
chemokine that may make the peptide useful as a...

Celltech lays claims to OGS

Celltech lays claims to OGS

UK biotechnology bellwether Celltech has emerged victorious in the
bidding battle for Oxford GlycoSciences. OGS reluctantly gave in to
Celltech's pressure on 11 April, after the latter firm bought
additional holdings which brought...

New patent for Chiral Quest

New patent for Chiral Quest

Life science company Chiral Quest this week announced that the
non-profit organisation, the Penn State Research Foundation, has
received a US patent covering the compositions of matter and use
for a series of chiral phosphine ligands...

New era for Roche

New era for Roche

Shareholders at Swiss pharmaceutical company Roche welcomed the
start of a new era as the company summarised recent events,
including the divestment of the vitamins business, at its annual
general meeting yesterday.